Closely-held Scientus Pharma updated its collaboration with Generex Biotechnology (OTCQB:GNBT) to co-develop products for the delivery of cannabinoids via the buccal mucosa, or inner lining of the mouth.
Having recently received Health Canada authorization to produce cannabis soft gel capsules and oils at its state-of-the-art, 45,000 sq. ft. commercial production facility in Whitby, Ontario, Scientus will turn its focus towards the final development of a buccal cannabis spray using Generex’s RapidMist technology.
“The ability to produce through our proprietary extraction and activation method an intermediary resin that is more than 99% activated for THC and CBD allows us to provide cannabis APIs at scale that can be incorporated into a variety of delivery methods, such as buccal spray, that were previously challenged by suboptimal potency and/or bioavailability,” Har Grover, chairman and CEO of Scientus, said in a statement.
“Our collaboration with Generex provides access to the drug delivery technology that will enable development of an effective cannabis buccal spray,” he added. “This route of administration is an attractive alternative to patients who have concerns about inhaling or eating medical cannabis, but still want its full therapeutic benefit.”
Joe Moscato, CEO of Generex, said the RapidMist Buccal Delivery System from Generex is perfectly suited to the formulation and administration of cannabinoids for therapeutic benefit.
He said THC and CBD ratios can be formulated specifically for therapeutic indications to achieve optimal benefit, and the device provides a consistent, reliable metered dose to ensure proper use. “Patients will be satisfied with the ease of use and reliability of effect of the RapidMist Cannabis product line,” he added.
